Tennessee is currently home to 1924 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
NCT04195347
Recruiting
This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemotherapy will be determined. The effectiveness in reducing the severity of pancreatitis will be estimated. Primary Objectives To assess the safety of CM4620 administration in children and young adults with asparaginase associated pancreatitis (AAP). To profile... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
06/30/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Pancreatitis
Register for Updates
TrialNet Pathway to Prevention of T1D
NCT00097292
Recruiting
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Gender:
ALL
Ages:
Between 2 years and 45 years
Trial Updated:
06/30/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Diabetes Mellitus, Type 1
Register for Updates
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117
Recruiting
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2025
Locations: Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee
Conditions: Solid Tumor, MET Alteration
Register for Updates
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
NCT06415487
Recruiting
ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2025
Locations: Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Utility of PCD Diagnostics to Improve Clinical Care
NCT03704207
Recruiting
This is a study evaluating the utility of current Primary Ciliary Dyskinesia (PCD) diagnostic tests, including nasal nitric oxide testing.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
06/28/2025
Locations: Vanderbilt Children's hospital, Nashville, Tennessee
Conditions: Primary Ciliary Dyskinesia
Register for Updates
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880
Recruiting
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: GSK Investigational Site, Nashville, Tennessee
Conditions: Neoplasms, Prostate
Register for Updates
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231
Recruiting
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/27/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Multiple System Atrophy
Register for Updates
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
NCT06834282
Recruiting
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/27/2025
Locations: Sarah Cannon Research Insitute, Nashville, Tennessee
Conditions: AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Register for Updates
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Holston Medical Group_Bristol, Bristol, Tennessee
Conditions: Obesity
Register for Updates
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/27/2025
Locations: Alkermes Investigator Site, Cordova, Tennessee
Conditions: Narcolepsy Type 2
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: StatCare Pulmonary Consultants, Knoxville, Tennessee
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100
Recruiting
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Focal Onset Seizures
Register for Updates